Dynamic QRS-complex ST-segment monitoring acute myocardial infarction recombinant tissue-type plasminogen activator therapy TEAHAT Study Group Changes QRS complex electrocardiographic expression irreversible injury myocardium humans process infarction several hours rapid development QRS changes patients thrombolytic agents Patients acute myocardial infarction AMI placebo-controlled trial mg recombinant tissue-type plasminogen activator rt-PA hours continuous on-line vectorcardiography magnitude QRS vector changes infarct size maximal value lactate left ventricular ejection fraction days randomization Treatment intravenous rt-PA limited total QRS vector change QRS vector changes plateau minutes patients rt-PA placebo certain pattern variable ST vector magnitude maximal lactate values vs mu kat/liter tendency mortality patients pattern patients pattern rt-PA maximal lactate time creatine kinase final magnitude QRS vector change 